• 2010     Dr. med. (medical doctorate), Faculty of Medicine, Saarland University, Homburg, Germany; Supervisors: Renner C., Knuth, Title: “Serologische Identifikation von Pankreaskarzinom-spezifischen Antigenen".
• 2007     Graduation from Medical School and German Licence to practice Medicine. Faculty of Medicine, Saarland University, Homburg, Germany, with electives in Bordeaux, France, Zürich, Switzerland and Homburg, Germany.

• 2024 Wilhelm-Vaillant-Award for Medical Research 2024
• 2024 Rolf Becker Award for Medical Research 2024
• 2024 European Research Council (ERC) Consolidator Grant
• 2023 Georges-Köhler Award, German Society for Immunotherapy, Germany.
• 2022 Cancer Research Award of the Berlin-Brandenburg Academy of Science, sponsored by the Monika-Kutzner Foundation.
• 2021 Lisec-Artz Award for Cancer Research, Medicine Faculty – University of Bonn, Germany.
• 2020 Clinical Science Award, German Society for Immunotherapy, Germany.
• 2019 M4-preseed Award by the Bavarian Ministry of Economical Affairs.
• 2019 Johann-Georg-Zimmermann Award for Cancer Research, University of Hannover, Germany.
• 2017 European Research Council (ERC) Starting Grant, Brussels, Belgium.
• 2017 Hugo-Wilhelm- von Ziemsen Award for medical research, Department of Internal Medicine IV, University Hospital of Ludwig-Maximilian University Munich (KUM), Germany.
• 2016 Vincenz-Czerny Award for Cancer Research, German Society of Hematology and Oncology, Germany.
• 2016 BMS-MRA Young Investigator Award, awarded by the Melanoma Research Alliance, Washington D.C., USA.
• 2016 Career Advancement Award 2016 of the Jung-Foundation for Science and Research, Hamburg, Germany.
• 2016 Young investigator Award, Melanoma Research Alliance, Washington D.C., USA.

• Bispecific antibody molecules with antigen-transfected T cells and their use in medicine. Kobold S, Bourquin C, Castoldi R, Sustmann C, Niederfellner G, Klein C and Endres S. PCT/EP2013/051351.
• PD1-CD28 fusions proteins and their use in medicine. Kobold S and Endres S. PCT/EP2016/064195.
• CXCR6 transduced T cells for targeted tumor therapy. Kobold S, Grassmann S, Rapp M and Endres S. EP15190179.0, submitted on October 16th 2015.
• Improving adoptive cellular therapy. Kobold S, Geiger M, Sustmann C, Niederfellner G, Klein C and Endres S. EP16177203, submitted on June 30th 2016.
• CCR8 transduced T cells for targeted tumor therapy. Kobold S, Cadilha BL and Endres S. EP19161708.3, submitted on march 3rd 2019.
• CSF1R-targeted immunotherapies. Kobold S, Lesch S, Gottschlich A, Endres S. EP21191376, submitted on August 13th 2021.

• 2025     Section Editor, European Journal of Cancer (JIF 7,6)
• 2023     Section Editor at the Journal for the Immunotherapy of Cancer (JIF 12.5), official journal of the Society for the Immunotherapy of Cancer (SITC).
• 2022     Editorial Board Member, ESMO IOTECH.
• 2020     Associate Editor for the Section Cancer Immunity and Immunotherapy. Frontiers in Immunology (JIF 5) and Frontiers in Oncology (JIF 4.8).

Total citations: 11.559; h-index: 55; h-index since 2021: 45 (Google Scholar January 21th, 2026)

Top-10 selected Publications

1. Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, Kobold S. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1536-1552. doi: 10.1182/blood.2023022197. PMID: 40178843

2. Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S*, Böttcher JP*. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature, 2024; May;629(8011):417-425. * share senior authorship. doi: 10.1038/s41586-024-07254-x. PMID: 38658748

3. Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S*, Binder M*. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. Nature Communications, 2024; Feb 2;15(1):993. * share senior authorship. doi: 10.1038/s41467-024-45378-w. PMID: 38307904.

4. Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S*, Funke JJ*, Dietz H*. Programmable multispecific DNA-origami-based T-cell engagers. Nat Nanotechnology, 2023; Nov;18(11):1319-1326. doi: 0.1038/s41565-023-01471-7. * share senior authorship. PMID: 37591933

5. Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnology, 2023; Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0. PMID: 36914885

6. Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity, 2023; Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010. PMID: 36630913

7. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, and Kobold S. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. Journal for the Immunotherapy of Cancer, 2022;10(7):e005054. doi: 10.1136/jitc-2022-005054. PMID: 35902133

8. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nature Reviews Cancer. 2021 Aug;21(8):481-499. doi: 10.1038/s41568-021-00363-z. PMID: 34083781

9. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021; Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6. PMID: 34083764

10. Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S and Kobold S. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cells to reject solid tumors. Science Advances, 2021; 7(24):eabi5781. doi: 10.1126/sciadv.abi5781. PMID: 34108220